ASAM's First National Medetomidine Guidance: Treat the Breathing, Not the Sleepiness
ASAM released the first national guidance on medetomidine intoxication and withdrawal on Nov. 10. Here is what it changes for patients and their families.

On November 10, the American Society of Addiction Medicine published the first national clinical guidance for a problem most treatment programs did not have a protocol for a year ago. The subject is medetomidine — a veterinary sedative that has moved into the unregulated fentanyl supply, and whose withdrawal does not behave like any withdrawal the field was trained on.
The document, ASAM Clinical Considerations: Medetomidine Intoxication and Withdrawal, was approved by ASAM's Quality Improvement Council and Board of Directors in October and posted today. The evidence base is too thin for a formal practice guideline, so this is a consensus document built from 529 screened studies, 46 of which met inclusion criteria, plus an expert committee's clinical experience.
That caution is itself the news: the largest addiction-medicine society in the United States has concluded the standard playbook does not cover this drug.
The first thing it changes: what naloxone is for
Most overdoses involving medetomidine also involve fentanyl, so naloxone remains the first move. But the guidance is explicit about the target: give naloxone in incremental doses only until breathing is adequately restored, and stop there.
Titrating naloxone to wakefulness is listed in the document as a specific management pitfall. Naloxone reverses opioids; it does not reverse medetomidine. A person can be breathing normally and still be deeply sedated, and that residual sedation is a reason to keep watching them — not a reason to give more naloxone.
That cuts both ways. A family told "if naloxone doesn't wake them, give another dose" may keep pushing naloxone into someone whose opioids are already reversed, while the actual risk — aspiration, low blood pressure, a heart rate in the thirties — goes unaddressed. Once respirations are adequate, the guidance says to manage the rest supportively, expecting three to six hours of observation before acute intoxication resolves.
Two syndromes, not one
Intoxication and withdrawal from medetomidine look nothing alike, and the guidance treats them as separate clinical problems.
Intoxication is persistent sedation with a slow heart rate — sinus bradycardia, sometimes in the 30 to 40 beats-per-minute range — and often low blood pressure that usually responds to IV fluids.
Withdrawal is the opposite: a hyperadrenergic storm that begins far sooner than opioid withdrawal does. ASAM puts onset at roughly three to four hours after last use, against six to 24 hours for opioids alone, and warns that it can escalate over the following day. The severe picture includes heart rates above 140 and sometimes above 170, hypertensive urgency or emergency, intractable vomiting, tremor, agitation, drenching sweats, and encephalopathy. Some patients develop muscle contractions and opisthotonus that get mistaken for a seizure. Complications include prolonged QTc, troponin elevation, cardiomyopathy and posterior reversible encephalopathy syndrome.
The document is blunt about magnitude: in parts of Pennsylvania with the highest measured concentrations in the supply, one bag of fentanyl-medetomidine could contain an amount of dexmedetomidine roughly 100 times a typical ICU loading dose.
Why the usual withdrawal medicines do not work
Benzodiazepines and phenobarbital — the workhorses for alcohol and benzodiazepine withdrawal — do not relieve this syndrome. Neither do full opioid agonists, which are otherwise effective for opioid withdrawal. The reason is mechanistic: medetomidine is an alpha-2 adrenergic agonist, 100- to 200-fold more potent at that receptor than xylazine, and its withdrawal is an alpha-2 problem, not a GABA or opioid problem.
What does work, according to the guidance, is more of the same class. Oral clonidine is first-line, and the doses are not the ones on the label. The document notes that while the typical maximum daily clonidine dose is 1.2 mg, severe medetomidine withdrawal has been managed with loading doses of 1 mg to more than 1.5 mg given in divided doses over one to four hours, then 0.1 to 0.3 mg every two to six hours with titration against symptoms and vital signs. Guanfacine and tizanidine are adjuncts; IV dexmedetomidine is reserved for severe or refractory cases, usually 24 to 72 hours, at rates up to 2.5 mcg/kg/hr — against an FDA-approved ICU ceiling of 0.7.
Vomiting is often refractory to ondansetron and is treated instead with IV or IM dopamine antagonists such as olanzapine, haloperidol, droperidol or prochlorperazine, with ECG monitoring because of QTc risk. This is a level of medication intensity that a standalone detox bed is not set up to deliver.
The mistake the guidance warns about by name
Families research. Someone three days into a hard withdrawal will find, quickly, that veterinarians reverse medetomidine sedation with an alpha-2 antagonist — and that the drug is sold online.
The guidance addresses this directly. Alpha-2 adrenergic antagonists are not approved or recommended for human use, and in someone with sustained or chronic medetomidine exposure they may precipitate a severe and potentially dangerous withdrawal. Buying a veterinary reversal agent is not a shortcut. It is a way to turn a managed withdrawal into an emergency.
The second named pitfall is quieter and lives inside treatment settings. Medetomidine withdrawal inflates standard opioid withdrawal scores, because the symptoms overlap — tachycardia, hypertension, nausea, vomiting, tremor, agitation, sweating. The guidance warns that a COWS score of 13 or higher recorded within a few hours of last use may reflect medetomidine withdrawal rather than opioid withdrawal, and that giving a standard buprenorphine dose on that basis risks precipitated withdrawal. Its recommendation is low-dose buprenorphine initiation with full-agonist bridging, or methadone per standard protocol. If you or someone you love is being inducted onto buprenorphine in an area where medetomidine is common, that is a question worth asking out loud.
What to do if this affects you or someone you love
- If you use drugs: do not use alone, and use less than usual. Carry naloxone and use it if breathing slows — but do not expect it to wake someone up, and do not leave a sedated person unwatched because the naloxone "worked."
- Test your supply if you can. Medetomidine strips exist at some harm reduction and syringe programs; San Diego County's advisory names its own, and 2-1-1 confirms what is stocked. Fentanyl strips say nothing about medetomidine.
- Treat the third hour seriously. Onset is fast. If someone who uses fentanyl stops and within a few hours has a pounding heart, rising blood pressure, vomiting they cannot stop, heavy tremor or confusion, go to an emergency department rather than waiting it out.
- Say the word at the hospital. Toxicology screens do not include medetomidine, and the guidance says diagnosis is clinical. Telling triage "I think this is medetomidine withdrawal" is not an overstatement — it is the diagnostic information the clinician does not otherwise have.
- Ask about the level of care. ASAM places mild withdrawal at ASAM Criteria Levels 2.7 or 3.7 with nurse monitoring, and moderate-to-severe withdrawal in a hospital, often with ICU capability. Someone stabilized in an emergency department may need a Level 3.7 medically managed residential program to finish a clonidine taper with vital-sign monitoring, rather than an ordinary detox bed.
Where the funding question sits
The guidance ends with a policy statement that will matter to families more than any dosing table: it calls it critically important that Medicare, Medicaid and other payers cover Level 3.7 medically managed residential care, because that is where the taper and monitoring happen. The difference from ASAM's earlier advocacy is that the clinical rationale now sits inside a national document payers can be pointed to.
Where to get help
- Emergency: call 911. If someone is unresponsive or breathing too slowly, give naloxone and call — and be ready to tell responders medetomidine may be involved.
- 988 Suicide & Crisis Lifeline: call or text 988, 24/7.
- SAMHSA National Helpline: 1-800-662-4357, free and confidential, 24/7, English and Spanish.
- FindTreatment.gov: searchable treatment locator, including sliding-scale and Medicaid-accepting programs.
- Never Use Alone: 1-800-484-3731, a call line for people who are going to use alone.
For how medetomidine was confirmed in one county's supply while its surveillance recorded zero cases, see our November 7 alert; for the hospital data that first described this syndrome, our September 29 report. To understand levels of care well enough to argue for one, this guide covers the ASAM Criteria.
The bottom line
Medetomidine is not a hypothetical. It was first detected in the drug supply in 2021, was reported nationwide by December 2025, and in some mid-Atlantic regions contaminates as much as 90% of the opioid supply. As recently as a year ago, a person arriving at an emergency department with this withdrawal was a clinical curiosity. Now there is a national document describing what to do.
The practical content for a family is smaller than the document: naloxone to restore breathing, not consciousness; veterinary reversal drugs are not a home remedy; withdrawal from this adulterant starts in hours and escalates fast; and when it does, the right answer is an emergency department that knows the word.
Sources
- ASAM — Clinical Consideration: Medetomidine Intoxication and Withdrawal (November 10, 2026)
- ASAM — ASAM Releases New Guidance for Managing Medetomidine Intoxication and Withdrawal (Nov. 10, 2026)
- CDC Health Alert Network — Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome (CDCHAN-00527, April 2, 2026)
- CAHAN San Diego — Health Advisory: Medetomidine in the San Diego County Drug Supply (October 29, 2026)
- Psychiatric Times — New National Guidance for Managing Medetomidine Intoxication and Withdrawal (November 10, 2026)
- SAMHSA National Helpline
- SAMHSA — FindTreatment.gov
You might also read


